Prot# 102-21: An Open Label Study of the Efficacy and Safety of Re-Treatments with Rituximab (MabThera®/Rituxan®) in Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies